Table 2. Abundance of N-glycan profilings in LCMM, IgG MM, IgA MM patients and healthy controls.

Peaks	Healthy control (n = 42)	LCMM (κ 19, λ 23)	IgG MM (κ 20, λ 22)	IgA MM (κ 22, λ 19)	P1	P2	P3
Peak 1	7.79 ± 1.94	6.95 ± 2.96	13.68 ± 12.48	4.82 ± 3.25	NS	0.001	0.001
Peak 2	1.30 ± 0.45	0.91 ± 0.54	1.52 ± 2.50	0.65 ± 0.41	<0.001	NS	0.022
Peak 3	6.32 ± 1.11	3.42 ± 1.39	11.97 ± 8.38	2.50 ± 1.85	<0.001	<0.001	0.003
Peak4	5.61 ± 1.22	4.12 ± 0.85	6.31 ± 2.54	3.24 ± 1.02	<0.001	<0.001	<0.001
Peak 5	38.76 ± 3.06	47.42 ± 6.37	30.82 ± 13.86	40.59 ± 8.86	<0.001	<0.001	<0.001
Peak 6	20.14 ± 2.54	14.73 ± 5.56	21.16 ± 10.45	22.45 ± 7.77	<0.001	<0.001	<0.001
Peak 7	6.21 ± 1.40	2.68 ± 2.61	3.33 ± 3.46	13.28 ± 12.93	<0.001	NS	<0.001
Peak 8	7.80 ± 1.96	10.03 ± 3.48	5.90 ± 2.96	6.15 ± 2.92	0.002	<0.001	<0.001
Peak 9	2.68 ± 1.28	5.04 ± 3.18	2.80 ± 1.89	3.46 ± 2.27	<0.001	<0.001	0.017
Peak 10	0.34 ± 0.13	0.46 ± 0.23	0.31 ± 0.23	0.36 ± 0.22	0.039	<0.001	0.043
Peak 11	1.69 ± 0.61	3.01 ± 1.34	1.57 ± 0.82	1.66 ± 0.85	<0.001	<0.001	<0.001
Peak 12	0.47 ± 0.24	1.23 ± 0.72	0.64 ± 0.44	0.84 ± 0.60	<0.001	<0.001	0.009

Note: Measurement data are expressed as means ± standard deviations;

P1: comparison between LCMM and healthy control,

P2: comparison between LCMM and IgG MM,

P3: comparison between LCMM and IgA MM;

Abbreviations: LCMM, light chain multiple myeloma;

IgG MM, IgG type multiple myeloma;

IgA MM, IgA type multiple myeloma;

NS, none-significant.